The Journal of Practical Medicine >

2025 , Vol. 41 >Issue 2: 162 - 169

DOI: https://doi.org/10.3969/j.issn.1006-5725.2025.02.002

Basic Research

Gypenosides LI down⁃regulates CPT1B through the pathway of lipid metabolism to inhibit the growth of colon cancer

  • Wenyu ZHU ,
  • Hongwei ZHANG ,
  • Decai TANG ,
  • Fangyuan CHEN ,
  • Hua JIANG ,
  • Haiyan MIN ,
  • Jie. DING
Expand
  • *.Department of Cancer Center，the Third Affiliated Hospital of Nanjing Medical University，Changzhou Second People′s Hospital，Changzhou 213000，Jiangsu，China

Received date: 2024-09-13

  Online published: 2025-01-26

Fold

Abstract

Objective To elucidate the mechanism through which Gypenoside L inhibits the growth of colon cancer by modulating carnitine palmitoyltransferase 1B （CPT1B）， a pivotal enzyme in the fatty acid metabolism pathway. Methods Through in vitro experiments， various concentrations of Gypenoside LI LI were applied to intervene in colon cancer RKO and SW620 cells. The effects of Gypenoside LI on these cells were comprehensively evaluated using the CCK?8 assay， wound healing assay， colony formation assay， and live?dead cell staining， focusing on its impact on cell proliferation， migration， and apoptosis. Additionally， a human colon cancer tissue microarray （TMA） was utilized in conjunction with multiplex fluorescence immunohistochemistry to analyze the expression of CPT1B in colon cancer and adjacent tissues. SW620 cells were transfected with siRNA， and the mRNA and protein expression levels of CPT1B post?transfection were assessed using quantitative real?time PCR （qPCR） and Western blotting. Furthermore， an in vivo nude mouse colon cancer model was established to investigate the inhibitory effect of Gypenoside LI LI on colon cancer growth. Results In vitro experiments demonstrated that Gypenoside LI LI effectively inhibited the proliferation and migration of RKO and SW620 cells in a concentration? and time?dependent manner. Additionally， multiple fluorescence immunohistochemistry analyses revealed that the expression level of CPT1B in colon cancer tissues was significantly higher than that in adjacent non?tumor tissues. Gypenoside LI LI promoted ROS accumulation by inhibiting CPT1B expression. In vivo experiments further confirmed that Gypenoside LI LI could inhibit tumor formation in nude mice and reduce CPT1B expression. Conclusions This study elucidates the mechanism by which Gypenoside LI inhibits the growth of colon cancer cells. Specifically， it downregulates CPT1B， leading to increased accumulation of reactive oxygen species （ROS）， disruption of fatty acid oxidation metabolism， and ultimately inducing apoptosis in colon cancer cells. These findings offer valuable insights into colon cancer treatment， suggesting new therapeutic strategies and potential drug targets.

Key words： Gypenoside LI; carnitine Palmitoyltransferase 1b （CPT1B）; colon cancer; fatty acid metabolism; drug target

Cite this article

Wenyu ZHU , Hongwei ZHANG , Decai TANG , Fangyuan CHEN , Hua JIANG , Haiyan MIN , Jie. DING . Gypenosides LI down⁃regulates CPT1B through the pathway of lipid metabolism to inhibit the growth of colon cancer[J]. The Journal of Practical Medicine, 2025 , 41(2) : 162 -169 . DOI: 10.3969/j.issn.1006-5725.2025.02.002

References

1 SIEGEL R L， MILLER K D， SAUER A G，et al.Colorectal cancer statistics， 2020［J］.CA Cancer J Clin， 2020， 70（3）：145-164. doi:10.3322/caac.21601
2 国家卫生健康委员会医政司， 中华医学会肿瘤学分会. 国家卫健委中国结直肠癌诊疗规范（2023版）［J］. 中国实用外科杂志， 2023， 43（6）： 602-630. doi:10.19538/j.cjps.issn1005-2208.2023.06.02
3 中华医学会肿瘤学会结直肠肿瘤学组. 直肠癌外科手术切缘中国专家共识（2024版）［J］. 中华胃肠外科杂志， 2024， 27（6）：545-558.
4 解园，靳语书，辛鑫，等. 肿瘤代谢相关治疗靶点及药物研究进展［J］.肿瘤学杂志， 2023， 29（9）：783-786.
5 郑一帆，黄咏彤，张永成，等. 氨基酸代谢重编程在肿瘤细胞及肿瘤相关巨噬细胞极化中的作用研究进展［J］. 山东医药， 2023， 63（12）：111-114.
6 陈惠，乔瑞，韩萌，等. 肿瘤中糖代谢重编程的研究进展［J］.宁夏医科大学学报， 2022， 44（11）：1170-1175.
7 LUO X， TU Z， CHEN H， et al. Blood lipids and risk of colon or rectal cancer： A Mendelian randomization study［J］. J Cancer Res Clin Oncol， 2021， 147（12）：3591-3599. doi:10.1007/s00432-021-03790-5
8 RESEARCH AND PRACTICE G. Retracted： The Effect and Related Mechanism of Action of Astragalus Compatible with Curcumin against Colon Cancer Metastasis in Mice［J］. Gastroenterol Res Pract， 2023， 2023：9793254. doi:10.1155/2023/9793254
9 WANG X， PAN S， CHEN L， et al. Sijunzi decoction enhances sensitivity of colon cancer cells to NK cell destruction by modulating P53 expression［J］. J Ethnopharmacol， 2024， 329：118115. doi:10.1016/j.jep.2024.118115
10 SUN X， HONG Y， SHU Y， et al.The involvement of Parkin-dependent mitophagy in the anti-cancer activity of Ginsenoside［J］. J Ginseng Res， 2022， 46（2）：266-274. doi:10.1016/j.jgr.2021.06.009
11 李华，王捷虹. PI3K/Akt通路调控结直肠癌机制及中医药治疗研究进展［J］. 中国实验方剂学杂志， 2023，29（13）：254-263.
12 陈宣，刘红宁，尚广彬，等. 养阴化瘀解毒方通过PI3K/Akt信号通路调控低氧环境下结肠癌细胞的自噬和凋亡［J］. 中国实验方剂学杂志， 2023，29（20）：45-53.
13 南京中医药大学. 中药大辞典［M］. 上海： 上海科学技术出版社， 2006： 2459-2463.
14 潘峰，刘迪，黄翠霞，等.绞股蓝皂甙的药理与临床研究［J］.现代中西医结合杂志， 2006， 15（5）：674-676.
15 YAN H， WANG X， NIU J， et al. Anti-cancer effect and the underlying mechanisms of gypenosides on human colorectal cancer SW-480 cells［J］. PLoS One， 2014， 9（4）：e95609. doi:10.1371/journal.pone.0095609
16 ZU M L， DUAN Y， XIE J B， et al. Gypenoside LIarrests the cell cycle of breast cancer in G0/G1 phase by down-regulating E2F1［J］.J Ethnopharmacol， 2021，273：114017. doi:10.1016/j.jep.2021.114017
17 LIU L， MO M， CHEN X， et al. Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer［J］. J Exp Clin Cancer Res，2023，42（1）：85. doi:10.1186/s13046-023-02647-8
18 JIANG C， LIU Y， WEN S， et al. In silico development and clinical validation of novel 8 gene signature based on lipid metabolism related genes in colon adenocarcinoma［J］. Pharmacol Res，2021，169：105644. doi:10.1016/j.phrs.2021.105644
19 WANG Y， LU J， WANG F， et al. Inhibition of fatty acid catabolism augments the efficacy of oxaliplatin-based chemotherapy in gastrointestinal cancers［J］. Cancer Lett，2020，473：74-89. doi:10.1016/j.canlet.2019.12.036
20 ABUDUREXITI M， ZHU W， WANG Y，et al. Targeting CPT1B as a potential therapeutic strategy in castration‐resistant and enzalutamide‐resistant prostate cancer［J］. Prostate， 2020， 80（12）：950-961. doi:10.1002/pros.24027
21 MENENDEZ J A， LUOU R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis［J］. Nat Rev Cancer，2007，7（10）：763-777. doi:10.1038/nrc2222
22 XIONG X， WEN Y A， FAIRCHILD R， et al. Upregulation of CPT1A is essential for the tumor-promoting effect of adipocytes in colon cancer［J］. Cell Death Dis， 2020， 11 （9）： 736-736. doi:10.1038/s41419-020-02936-6
23 CHAVES-FILHO A B， PEIXOTO A S， CASTRO é， et al. Futile cycle of β-oxidation and de novo lipogenesis are associated with essential fatty acids depletion in lipoatrophy ［J］. Biochim Biophys Acta Mol Cell Biol， 2023， 1868 （3）： 159264. doi:10.1016/j.bbalip.2022.159264
24 WANG Y N， ZENG Z L， LU J， et al. CPT1A-mediated fatty acid oxidation promotes colorectal cancer cell metastasis by inhibiting anoikis ［J］. Oncogene， 2018， 37 （46）： 6025-6040. doi:10.1038/s41388-018-0384-z
25 WENG L， TANG W S， WANG X， et al. Surplus fatty acid synthesis increases oxidative stress in adipocytes and lnduces lipodystrophy［J］. Nat Commun， 2024， 15 （1）： 133. doi:10.1038/s41467-023-44393-7
26 SERENA C， FABIO C， PAMELA F D， et al. Adaptive antioxidant response to mitochondrial fatty acid oxidation determines the proliferative outcome of cancer cells［J］. Cancer Lett， 2023， 554：216010. doi:10.1016/j.canlet.2022.216010
27 BULBUL A， SYLVANUS K， MUHAMMAD K， et al. Rg3 inhibits gemcitabine-induced lung cancer cell invasiveness through ROS-dependent， NF-κB- and HIF-1α-mediated downregulation of PTX3［J］. J Cell Physiol， 2019， 234（7）： 10680-10697. doi:10.1002/jcp.27731
28 HEDIEH K， REZA M S， HOSSEIN M G， et al. Acetyl-L-Carnitine Attenuates Arsenic-Induced Oxidative Stress and Hippocampal Mitochondrial Dysfunction［J］. Biol Trace Elem Res， 2017， 184 （2）： 422-435. doi:10.1007/s12011-017-1210-0
Options
Outlines

/

〈 〉